全文获取类型
收费全文 | 7781篇 |
免费 | 788篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 38篇 |
儿科学 | 146篇 |
妇产科学 | 126篇 |
基础医学 | 699篇 |
口腔科学 | 70篇 |
临床医学 | 1442篇 |
内科学 | 2063篇 |
皮肤病学 | 236篇 |
神经病学 | 947篇 |
特种医学 | 231篇 |
外科学 | 1035篇 |
综合类 | 84篇 |
一般理论 | 2篇 |
预防医学 | 570篇 |
眼科学 | 130篇 |
药学 | 425篇 |
中国医学 | 10篇 |
肿瘤学 | 349篇 |
出版年
2023年 | 97篇 |
2022年 | 34篇 |
2021年 | 187篇 |
2020年 | 157篇 |
2019年 | 150篇 |
2018年 | 220篇 |
2017年 | 198篇 |
2016年 | 209篇 |
2015年 | 247篇 |
2014年 | 319篇 |
2013年 | 412篇 |
2012年 | 445篇 |
2011年 | 463篇 |
2010年 | 365篇 |
2009年 | 409篇 |
2008年 | 408篇 |
2007年 | 328篇 |
2006年 | 368篇 |
2005年 | 364篇 |
2004年 | 308篇 |
2003年 | 290篇 |
2002年 | 277篇 |
2001年 | 151篇 |
2000年 | 102篇 |
1999年 | 110篇 |
1998年 | 101篇 |
1997年 | 148篇 |
1996年 | 139篇 |
1995年 | 139篇 |
1994年 | 104篇 |
1993年 | 99篇 |
1992年 | 87篇 |
1991年 | 62篇 |
1990年 | 58篇 |
1989年 | 73篇 |
1988年 | 73篇 |
1987年 | 52篇 |
1986年 | 55篇 |
1985年 | 51篇 |
1984年 | 55篇 |
1983年 | 46篇 |
1982年 | 43篇 |
1980年 | 43篇 |
1979年 | 37篇 |
1978年 | 30篇 |
1976年 | 24篇 |
1975年 | 26篇 |
1974年 | 33篇 |
1973年 | 36篇 |
1972年 | 24篇 |
排序方式: 共有8603条查询结果,搜索用时 31 毫秒
1.
2.
3.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
4.
Emarene Kalaw Malcolm Lim Jamie R. Kutasovic Anna Sokolova Lucinda Taege Kate Johnstone James Bennett Jodi M. Saunus Colleen Niland Kaltin Ferguson Irma Gresshoff Mark Bettington Nirmala Pathmanathan Gary M. Tse David Papadimos Rajadurai Pathmanathan Gavin Harris Rin Yamaguchi Puay Hoon Tan Stephen Fox Sandra A. O’Toole Peter T. Simpson Sunil R. Lakhani Amy E. McCart Reed 《British journal of cancer》2020,123(11):1665
5.
Femoral access‐related complications during percutaneous transcatheter aortic valve implantation comparing single versus double Prostar XL device closure 下载免费PDF全文
6.
Jessica Roberts MBBS Jason Powell MBBS MClinRes PhD MRCS Jacob Begbie MBBS MRes Gerard Siou MBBS MD FRCS Claire McLarnon MBBS MSc FRCS Andrew Welch MBBS FRCS Michael McKean MBChB MD FRCPCH Mathew Thomas MBChB MRCPCH PhD Anne-Marie Ebdon MBBS MRCPCH FRACP Samantha Moss MBBS MRCPCH MD Rachel S. Agbeko MSc MD PhD FRCPCH FFICM Jonathan H. Smith MBChB MRCP FRCA Malcolm Brodlie MB ChB PhD MRCPCH Christopher O'Brien MBBS FRCPCH Steven Powell MBBS MSc FRCS 《The Laryngoscope》2020,130(5):E375-E380
7.
8.
HOCK LEONG EE MBBS MRCP CHEE LEOK GOH MBBS FRCP KHOO ES-Y. CHAN PHD POR ANG MBBS MRCP 《Dermatologic surgery》2006,32(1):34-40
BACKGROUND: Acquired bilateral nevus of Ota-like macules (Hori's nevus) is a common dyschromatosis among Asian women. Q-switched lasers have been used successfully as a treatment modality. OBJECTIVE: The purpose of this study was to compare the efficacy of using the Q-switched 532 nm neodymium:yttrium-aluminum-garnet (Nd:YAG) laser followed by the 1,064 nm laser versus the Q-switched 1,064 nm Nd:YAG laser alone in the treatment of Hori's nevus. METHODS: This is a prospective left-right comparative study. Ten women with bilateral Hori's nevus were recruited and treated with a combination of the Q-switched 532 and 1,064 nm Nd:YAG lasers on the right cheek and the Q-switched 1,064 nm Nd:YAG laser alone on the left cheek. Only one laser treatment session was performed. The degree of pigmentation was objectively recorded with a mexameter. Subjective assessment was made by both patients and two blinded, nontreating dermatologists. RESULTS: At 6 months, there was a statistically significant difference (p = .009) of 35.10 points using objective mexameter measurements between the two sides, favoring the side treated with a combination of 532 and 1,064 nm laser treatment. Subjective grading by the patients and blinded dermatologists also confirmed that combination therapy was more successful after one treatment. Although combination treatment had a higher incidence of mild postinflammatory changes, this disappeared within 2 months. CONCLUSIONS: Concurrent use of the Q-switched 532 nm Nd:YAG laser in combination with the 1,064 nm laser is more effective in pigment clearance than the Q-switched 1,064 nm Nd:YAG laser alone for Hori's nevi. 相似文献
9.
Dr. Arthur A. Dunk MRCP Natasha Kyprianou MSc Peter Davies PhD Howard C. Thomas PhD FRCP 《Digestive diseases and sciences》1988,33(4):472-476
Castrated or sham-operated male athymic mice were inoculated with cells from the human hepatocellular carcinoma cell line PLC/PRF/5. There were no significant differences between the two groups with respect to the number of animals developing tumors, the time to tumor development, or the subsequent rate of increase in either tumor base area or mouse serum alpha-fetoprotein concentration. Androgen receptors were assayed in nuclei obtained from three separate liver cancer cell lines and from normal adult human liver. Similar concentrations, ranging from 235 to 550 fmol/mg DNA, of nuclear androgen receptors were detected in all tissues. Low percentages of androgen receptors were retained on DNA-cellulose. Although the presence of receptors implies the potential for metabolic effects of androgens in normal and malignant liver, our in vivostudies suggest that castration does not alter significantly the growth of liver cancer xenografts in athymic mice. 相似文献
10.
Gavin Wright 《ANZ journal of surgery》2005,75(11):952-952